Centrexion farms out pain drug to Lilly in deal worth up to $998M
29 May 2019 //
FIERCE BIOTECH
Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal
28 May 2019 //
BIOSPACE
A bruised Eli Lilly buys rights to Centrexion’s pain drug for $47.5M upfront
28 May 2019 //
ENDPTS

Market Place
Sourcing Support